Merck's stock price went down a lot during Tuesday's trading session because they reported their financial results for the second quarter and said that they think they will make less money in the next year than what people thought. This made some people worried and they decided to sell their shares of Merck, which made the price go down. Some other companies also had their stock prices go up or down for different reasons. Read from source...

- Article has multiple inconsistencies:
- Merck's share price decline is blamed on cutting FY24 adjusted EPS guidance below estimates, but the article itself states that EPS was a loss in the previous quarter, and cutting guidance could be a positive sign.
- QXO's share price decline is blamed on the registration of two private placements, but the article does not provide any evidence or explanation of how this caused the share price to fall by 80.8%.
- VBI Vaccines' share price decline is blamed on entering into an exclusive license agreement with Cortice Biosciences, but the article does not explain how this is a negative development or why it would cause such a drastic decline.
- Article has biases:
- The article titles Merck's share price decline as a "loss" despite the company beating revenue and adjusted EPS estimates, which implies a negative sentiment.
- The article quotes data from Benzinga Pro without providing any context or comparison, making it seem like the stock movements are more significant than they might be.
- Article has irrational arguments:
- The article claims that Merck's cut in FY24 adjusted EPS guidance below estimates is a "disappointment", but the company still expects to grow sales and adjusted EPS in 2023 and beyond.
- The article suggests that QXO's share price decline was caused by the registration of two private placements, but does not provide any evidence or explanation of how this caused the share price to fall by 80.8%.
- The article implies that VBI Vaccines' share price decline was caused by entering into an exclusive license agreement with Cortice Biosciences, but does not explain how this is a negative development or why it would cause such a drastic decline.
- Article has emotional behavior:
- The article uses words like "plunged", "fell sharply", "declined", and "tumbled" to describe the share price movements, which conveys a negative and dramatic tone.
- The article uses exclamation marks and capital letters in some headlines, which adds to the sensationalism and emotional appeal of the content.

### Final answer: The article is of poor quality and credibility, as it contains inconsistencies, biases, irrational arguments, and emotional behavior.

Merck & Co., Inc. MRK, Imunon, Inc. IMNN, Agape ATP Corporation ATPC, Processa Pharmaceuticals, Inc. PCSA, INVO Bioscience, Inc. INVO, Jet.AI Inc. JTAI, 2U, Inc. TWOU, CalciMedica, Inc. CALC, JetBlue Airways Corporation JBLU, Lumen Technologies, Inc. LUMN, Commvault Systems, Inc. CVLT, Harmonic Inc. HLIT, Meta Data Limited AIU, Enveric Biosciences, Inc. ENVB, Inspirato Incorporated ISPO, Sprouts Farmers Market, Inc. SFM, NeoGenomics, Inc. NEO, Tilray Brands, Inc. TLRY,